Drug resistance in patients treated with crizotinib has led to the introduction of the second-generation ALK inhibitors ceritinib and alectinib for the treatment of ALK-positive NSCLC (Table 4), but adverse CNS effects for these inhibitors are greater than for the first-generation ALK inhibitors. Here, ALK is linked to non-small cell lung carcinoma.